Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) lost 1.7%, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 2.8%. Novo Nordisk announced ...

A naturally occurring molecule that works as effectively as other semaglutide-based drugs — without the common side effects — ...

Discover the daily step count for weight loss, why the 10,000-step rule might be a myth, and ways to increase your walking ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

From stocking your kitchen with nutritious staples to making a few smart ingredient swaps, these expert-approved tips make ...

DEAR ABBY: My wife and I went for our annual checkups seven months ago. We were both overweight and told by our respective ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Budget hearings are over at the State Capitol, but one particular expense involving a popular weight loss drug has caught the ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.